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ABSTRACT 
Background: Kentucky ranks first in the US in cancer incidence and mortality. Compounded by 
high poverty levels and a high rate of medically uninsured, cancer rates are even worse in 
Appalachian Kentucky. Being one of the first states to adopt the Affordable Care Act (ACA) 
Medicaid expansion, insurance coverage markedly increased for Kentucky residents. The 
purpose of our study was to determine the impact of Medicaid expansion on colorectal cancer 
(CRC) screening, diagnosis, and survival in Kentucky. 
Study Design: The Kentucky Cabinet for Health and Family Services and the Kentucky Cancer 
Registry were queried for individuals (≥20 years) undergoing CRC screening (per US 
Preventative Services Task-Force) or diagnosed with primary invasive CRC from January 1, 
2011 to December 31, 2016. CRC screening rates, incidence, and survival were compared before 
(2011-2013) and after (2014-2016) ACA implementation. 
Results: CRC screening was performed in 930,176 individuals and 11,441 new CRCs were 
diagnosed from 2011-2016. CRC screening increased substantially for Medicaid patients after 
ACA implementation (+230%, p<0.001), with a higher increase of screening among the 
Appalachian (+44%) compared with the non-Appalachian (+22%, p<0.01) population. CRC 
incidence was increased after ACA implementation in individuals with Medicaid coverage 
(+6.7%, p<0.001). Additionally, the proportion of early stage CRC (stage I/II) increased by 9.3% 
for Appalachians (p=0.09), while there was little change for non-Appalachians (-1.5%, p=0.60). 
CRC survival was improved after ACA implementation (HR=0.73, p<0.01), particularly in the 
Appalachian population with Medicaid Coverage. 
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Conclusions: Implementation of Medicaid expansion led to a significant increase in CRC 
screening, CRC diagnoses, and overall survival in CRC patients with Medicaid, with an even 
more profound impact in the Appalachian population. 
 
 
KEYWORDS: Medicaid expansion; Appalachia Kentucky; colorectal cancer 
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FPL: Federal Poverty Level 
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INTRODUCTION 
Kentucky ranks first nationally in incidence and mortality of all site cancers.1,2 The Appalachian 
region of Kentucky heavily contributes to these poor outcomes, where cancer surpasses heart 
disease as the leading cause of death.2,3 The etiology of the disproportionately high cancer rate is 
multifaceted, but a major factor is the distressed socioeconomic status in Kentucky.2 For the past 
decade, Kentucky maintained the fifth highest poverty rate in the nation.4 Even worse, 
Appalachian Kentucky has the highest poverty rate in the nation at an astounding 1.7 times the 
national average. Of the 54 counties in Appalachia, 38 counties are economically distressed, or 
ranks in the bottom 10% of all US counties.5 
High poverty levels left a large portion of the Kentucky population uninsured and subsequently 
unable to seek preventative care.2,6-8 The Medicaid Expansion of the Patient Protection and 
Affordable Care Act (ACA) was incredibly successful in reducing the uninsured rate in 
Kentucky.9 The expansion, enacted in 2014, provided Medicaid coverage to those at 138% of the 
federal poverty level (FPL). Being one of the first two states to implement ACA, uninsured rates 
dropped in Kentucky by more than half from 13.6% pre-ACA to 6.1% two years post-ACA. At 
the same time, the national uninsured rate dropped from 14.7% to 9.4%. Medicaid Expansion in 
the neighboring state of Illinois had a slightly smaller impact; its uninsured rate dropped from 
12.9% to 7.0%. Conversely, Tennessee, a state that did not expand Medicaid, experienced a 
modest decrease in the uninsured rate (from 13.8% to 10.2%). The population most impacted by 
the expansion of Medicaid was those under 138% of national poverty level, which demonstrated 
a nearly threefold drop in the rate of uninsured individuals (from 25.0% to 9.4%).10 
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When looking specifically at colorectal cancer (CRC), Kentucky ranks first nationwide for 
incidence (50.0 cases per 100,000) and fifth for mortality (17.2 deaths per 100,000).1,2 As 
expected, Appalachian Kentucky has even higher incidence (55.1 cases per 100,000) and 
mortality (20.2 deaths per 100,000).2 Screening for CRC has been demonstrated to significantly 
decrease incidence and mortality.11,12 The US Preventative Services Task Force recommended 
screening for those beginning at the age of 50, with one of the following tests: high-sensitivity 
fecal occult blood testing annually, sigmoidoscopy every 5 years, or colonoscopy every 10 
years.13 In the past, Kentucky has reported low rates of CRC screening. In 1999, only 34.7% of 
the Kentucky population received CRC screening of any type, ranking 49th in the nation.14 These 
results prompted several state-wide screening initiatives including the establishment of the 
Kentucky Colon Cancer Screening Program and the Kentucky Colon Cancer Screening Advisory 
Committee in 2002. As a result, CRC screening rates improved to 65.9% in those 50 years or 
older in 2012. However, CRC screening rates, although improved in western and central 
Kentucky, remained low in eastern Appalachian Kentucky.15,16 The purpose of this study is to 
evaluate the effect of ACA Medicaid expansion on CRC screening, incidence, and survival in the 
Kentucky population with a particular focus on Appalachian Kentucky. 
METHODS 
Data Sources 
 
Kentucky CRC screening, incidence and outcomes data were obtained from two distinct 
databases. CRC screening data was obtained from the Kentucky Hospital Discharge Database, 
which resided in the Kentucky Cabinet for Health and Family Services (KHFS). Ethical approval 
for the utilization of this database was obtained from the University of Kentucky’s Office of 
7 
 
Research Integrity Institutional Review Board. The sample population included all patients older 
than 20 years old who underwent CRC screening from January 1, 2011 to December 31, 2016. 
Each screening occurrence was captured through the CPT code involving either screening or 
diagnostic colonoscopy, sigmoidoscopy, guaiac based fecal occult test, fecal immunochemical 
test or fecal DNA test. Each case was then confirmed with the ICD (9 and 10) code for screening 
visits, allowing for the capture of recoded endoscopic procedures from screening to diagnostic 
due to positive findings. 
CRC demographics, incidence, and cancer outcomes data in the state of Kentucky were obtained 
through the Institutional Review Board approved collaboration with the Kentucky Cancer 
Registry (KCR). A data use agreement was obtained between the investigator and KCR in April 
2018. The KCR is a population-based registry and has been awarded the highest level of 
certification by the North American Association of Central Cancer Registries for an objective 
evaluation of completeness, accuracy and timeliness every year since 1997. In addition, KCR is a 
National Cancer Institute Surveillance, Epidemiology, and End Results population-based cancer 
registry. The KCR also links its database annually with the State Death Certificate data and 
National Death Index to capture the most accurate survival information.17 The study population 
included all patients 20 years and older, who were diagnosed with CRC between January 1, 2011 
and December 31, 2016. Only the first invasive primary CRC was included in the analysis. Cases 
that were captured through autopsy or death certificates were excluded. Measures obtained 
include demographics (age at diagnosis, sex, race, metropolitan status, Appalachian status) and 
insurance coverage (Medicaid, Medicare, other public insurance, private insurance and no 
insurance) based on payer information at the time of diagnosis from the KCR. Other variables of 
interest such as socioeconomics (percentage below poverty status at the county level, high school 
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education ascertainment at the county level) and clinical information (tumor grade, stage at 
diagnosis and survival) were also included in the data analysis. 
For the purpose of this study, the post-ACA implementation time period was defined as the 
implementation of Medicaid expansion on January 1, 2014, to December 31, 2016. The pre-ACA 
period was defined as an equal length of time before ACA implementation from January 1, 2011 
to December 31, 2013. County of residence at time of discharge from the KHFS or time of 
diagnosis from the KCR were used to define patient’s geographic regions. Metropolitan status 
was based on the 2013 Urban-Rural Continuum codes with the values of 1-3 as urban and 4-9 as 
rural.18 The county-level Appalachian status was defined according to the Appalachia Regional 
Commission, as the 54 counties in Eastern Kentucky.5 The 2008-2012 American Community 
Survey was used to create the poverty status and high school education ascertainment variables, 
which were collapsed into four levels based on the quartiles of their distributions. Poverty status 
is categorized as: low (<16.2%), moderate (16.2-18.1%), high (18.2-21.7%), very high 
(>21.7%); education ascertainment is categorized as: very low (<75.8%), low (75.8-84.3%), 
moderate (84.4-88.0%), and high (88.1-91.8%). Stage at diagnosis was also categorized as early 
(Stage I and II) and late stage (Stage III and IV). Survival was defined as length of time from 
date of diagnosis to death or end of the study period. 
Statistical Analysis 
Descriptive analysis was conducted for all variables. Chi squared tests were performed to 
examine the association between ACA status and other covariates, stratified by insurance status. 
Kaplan-Meier plots and Log-Rank tests were conducted by ACA status for each insurance type 
separately. Cox regression analysis was performed to determine whether ACA status is 
associated with survival while controlling for other variables, Goodness of fit and proportional 
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hazard assumption were examined. Analyses were two-sided with a p-value ≤ 0.05 used to 
identify statistical significance. All analyses were performed using SAS Statistical Software 
version 9.4 (SAS Institute, Inc., Cary, North Carolina, USA). 
 
RESULTS 
 
Patient characteristics 
A total of 930,176 patients were screened for CRC from 2011 to 2016. The highest proportion of 
patients screened was in 2015, and the lowest proportion screened was in 2011 (Table 1). As 
expected, the highest proportion of those screened were in the age 51-65 group. Interestingly, 
8.2% of those screened were younger than 40 years old, which may be secondary to the high 
incidence of familial causes of CRC in Kentucky.19 More females were screened than males. The 
majority of patients who received screening were white (92.7%) and a small proportion were 
black (6.0%), which is slightly lower than the overall percentage of black patients in Kentucky 
(8.4%) demonstrating a screening disparity.20 When looking at insurance coverage, nearly half of 
those screened had private insurance (47.8%), while 9.7% of patients had Medicaid and 1.4% 
were uninsured. About a fourth of the patients who received screening were Appalachian. When 
looking specifically at the Medicaid subgroup, higher proportion of female (62.6%) and black 
patients (9.6%) received screening compared to all insurance types. Nearly half of the Medicaid 
patients who received screening were Appalachian (42.3%). 
Impact of ACA Expansion on CRC Screening 
A total of 408,500 patients were screened pre-ACA and 521,676 were screened after ACA 
implementation, an increase of 27.7% (Table 2). Colonoscopy was utilized as the major 
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screening method in 72.7% of patients. The 51-65 age group had the highest increase in 
screening, while both sexes increased proportionally. When comparing screening rates based on 
insurance coverage, patients with Medicaid demonstrated the highest increase in CRC screening. 
A total of 69,328 Medicaid patients received screening after ACA implementation compared to 
20,980 individuals who were screened pre-ACA, thus representing an increase of 230%. 
Screening rates for patients with private insurance increased by 10.2% and Medicare patients 
increased by 29.9%. Overall, 43.7% more Appalachian patients received CRC screening after 
ACA implementation compared to pre-ACA. 
When looking specifically at Medicaid patients, individuals in the 51-65 age group had the 
highest improvement in screening (+292.5%). There was also a higher proportional increase in 
screening in males compared to females after ACA implementation. The increase of coverage in 
all races remained proportional. Similar to the overall Kentucky trend, Medicaid coverage of 
Appalachian patients increased by 199.0% while uninsured Appalachian patients decreased by 
77.7% after ACA implementation (Figure 1). 
 
Impact of ACA Expansion on CRC Incidence 
 
 From January 1, 2011 to December 31, 2016, 11,441 Kentucky patients were diagnosed 
with CRC. After ACA Medicaid expansion, there was not a significant increase in incidence 
(5,665 pre-ACA vs. 5,776 after ACA implementation), but there was a change in the distribution 
(Table 3). The CRC incidence in the 20-49 age group increased by 22.8%, while the age 75-90 
group decreased by 7.5%, indicating a shift toward an increase in incidence in the younger 
population consistent with national CRC trends.21 When separated by insurance, the proportion 
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of Medicaid patients who were diagnosed with CRC increased by 132.4% after Medicaid 
expansion. In patients who had Medicaid, there were no significant differences in regard to 
poverty and education level indicating a similar population before and after ACA 
implementation. Consequently, there was a four-fold decrease in incidence in the uninsured 
group. 
When evaluating patients who had Medicaid coverage, there was an increase in Appalachian 
CRC incidence (87.8%) (Figure 2). When separating out incidence by stage in this group, the 
proportion of early stage diagnoses (stage I/II) increased by 9.3% for Appalachians (p=0.09), 
which was not noted in non-Appalachians (-1.5%, p=0.60). There was no effect on late stage 
diagnosis. 
 
Impact of ACA Expansion on CRC Survival 
 When evaluating the role of ACA expansion in CRC survival, both Medicaid and 
Appalachian patients benefited while uninsured patients suffered. After ACA implementation, 
Medicaid patients exhibited improved survival compared to patients prior to instituting ACA 
(Figure 3). Conversely, the remaining uninsured patients who did not receive coverage from 
ACA implementation had a worse survival compared to pre-ACA implementation. There were 
no significant differences in survival for private insurance and Medicare with regards to ACA 
expansion. Notably, the survival differences after ACA implementation was evident in Medicaid 
patients after the first year and increased each year thereafter (eTable 1). We noted an overall 
worse survival (HR 2.12, 95%, CI 1.23-3.67, p = 0.048) in the black uninsured population 
compared with the white population, consistent with national trends.22 This effect was not seen in 
any other insurance groups. 
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When controlling for age, sex, race, cancer stage and grade, cox regression analysis revealed all 
Medicaid patients had improved survival after ACA implementation compared to pre-ACA 
implementation (HR 0.73, 95% CI 0.58-2.11; p = 0.008). Interestingly, when looking specifically 
at Appalachian patients with Medicaid coverage, there was significantly improved survival after 
ACA implementation compared to the period pre-ACA (Figure 4). However, there was no 
difference in survival in the Medicaid non-Appalachian population, indicating the improvement 
in overall Medicaid patient survival after ACA implementation was heavily contributed by the 
Appalachian population. 
 
DISCUSSION 
 
ACA Medicaid expansion has had unprecedented success in providing Medicaid coverage for the 
uninsured population in Kentucky. Earlier studies demonstrated implementation of the expansion 
increased screening in prostate cancer,23 cervical cancer,24-26 and breast cancer.25,27 In Kentucky, 
improved coverage was also associated with earlier diagnosis of breast cancer and improved 
treatment quality.27 We set out to evaluate the impact of ACA expansion on CRC screening. We 
found the expansion of Medicaid in Kentucky significantly increased CRC screening, 
particularly in the Appalachian population. Moreover, ACA expansion was associated with 
increased CRC incidence in the Medicaid population with a shift toward early stage diagnosis in 
Appalachian patients. Importantly, we demonstrated for the first time that ACA expansion 
significantly increased CRC survival in both the Medicaid and Kentucky Appalachian 
populations. 
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Our study established the substantial impact of insurance coverage in amplifying CRC screening. 
Over the past two decades, Kentucky has implemented several programs to expand CRC 
screening.15 The major barriers to CRC screening include lack of insurance coverage and lack of 
provider recommendation.6-8,28,29 Our study demonstrated the ACA Medicaid expansion 
decreased the number of low-income uninsured patients in Kentucky which help to alleviate 
barriers to healthcare access. By 2015, in the second year of expansion, there was 12% increased 
access to PCPs, allowing greater than 85% of low-income patients to easily obtain physician 
visits.30 Improved healthcare system contact led to increased preventative screening by enabling 
access to PCPs.9 The Behavioral Risk Factor Surveillance System reported in 1999 the CRC 
screening rate in Kentucky was 34.7% compared to 43.9% nationally. CRC screening plateaued 
just before ACA implementation at 65.7%. After ACA implementation in 2014, screening in 
Kentucky further increased to 69.6% compared to 66.6% nationally.14,31 However, Appalachian 
Kentucky screening lagged behind, at 63.0%.2 The most recent 2016 data revealed further 
improvement of screening rates to 70.1% compared to 67.7% nationally.14,31 Similarly, we 
identified a more than threefold increase in CRC screening three years after Medicaid expansion. 
In Kentucky, additional insurance coverage increased CRC incidence immediately after ACA 
implementation. CRC incidence has steadily decreased over the past 40 years.32,33 
Microsimulation models suggest the largest contribution come from screening, while risk factor 
reduction and treatment improvements are minor contributors.33,34 Early detection of precursor 
lesions would have immediate reduction of CRC incidence within the first two years and 
maximal reduction by 15 years.32,34-38 We would expect immediate increased incidence in newly 
insured Medicaid patients as existing cancers are identified. In addition, this population may also 
have a shift toward earlier stage diagnosis.39,40 However, as expected, the removal of pre-
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cancerous lesions would decrease cancer progression leading to decreased incidence rates.11 
Similarly, we identified an increase of incidence in the Medicaid and Appalachian population 
immediately after ACA implementation. We demonstrated a trend toward higher rates of early 
stage (I and II) CRC diagnosis in the Appalachian population, which was not seen in the 
uninsured population. Because this study evaluated the short-term effects of Medicaid expansion, 
we would not expect a decrease in CRC incidence. 
CRC screening is very effective in reducing the cancer specific mortality risk. Zauber et al12 
demonstrated a 53% reduction of 10-year survival in patients who received a screening 
colonoscopy. In fact, the impact of CRC screening on survival continues for up to two decades.41 
Even so, CRC mortality in Kentucky remain behind national standards. In 2011-2015 the 
mortality rate of CRC nationally was 14.5 per 100,000 compared to 17.0 per 100,000 in the state 
of Kentucky.2 Appalachian Kentucky mortality was even higher, with a more profound benefit 
from screening.42,43 In just a short time interval After ACA implementation, we showed that 
Medicaid patients had a 27% lower risk of death compared to pre-ACA, while those who were 
uninsured had an overall worse survival. Notably, the Kentucky Appalachian patients also had a 
significantly improved survival associated with the dramatic expansion of Medicaid coverage as 
a result of increased CRC screening. 
We demonstrated a markedly improved survival in both the Medicaid and Kentucky Appalachian 
population in just a short time after ACA implementation. In fact, the significant survival 
improvement was evident within the first year. Similarly, several studies including a large 
metanalysis demonstrated a survival difference at 3 years after receiving CRC screening, with 
the maximal effect at 15 years.44,45 The short term effects of a CRC screening program 
implementation on survival was also found in a Kaiser Permanente health system demonstrating 
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a significant decrease in mortality within 4 years.11 Our survival follow-up time was greater than 
6 years for the pre-ACA group and greater than 4 years for the after ACA implementation group. 
As CRC incidence can drop within two years after improved screening, survival differences can 
be seen within our follow up time period partly due to early detection and treatment.35 
Importantly, the improved survival after ACA implementation was not evident in the private, 
Medicare and uninsured populations, indicating the specific association of survival after CRC 
screening with Medicaid patients. 
 The results of this study could be generalized to other states that have expanded Medicaid 
coverage. Nonetheless, there are several limitations to our current study. The CRC screening data 
may contain a small number of patients who underwent more than one screening procedure, thus 
was counted twice. However, it is extremely unlikely for a second procedure to be coded as a 
screening procedure, and more likely to be coded as a diagnostic procedure. In addition, prior to 
2016, post-hoc manipulation of CPT codes was legal. As a result, there may be a bias among the 
colonoscopies that had CPT codes converted from screening to diagnostic as a result of a 
positive finding during the procedure. This would have underestimated screening colonoscopies 
before 2016. Next, the significant survival benefit identified in the Medicaid population after 
ACA implementation may be contributed by other factors which were not included in the 
analysis. For example, prior to ACA implementation, only the most impoverished adults (less 
than half of FPL) were covered by Medicaid, whereas after implementation, the coverage 
included up to 138% of the FPL. This higher income group were likely more health conscious 
and had better access to care, which was evident by the decreased survival in the uninsured 
population, suggesting only patients with the lowest level of access remain uninsured after ACA 
implementation. However, these individual socioeconomic and health access factors were not 
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available for the data analysis. Lastly, cancer survival is also related to reliable quality treatment, 
which is not accounted in our survival analysis. However, due to our demonstration of 
improvement in survival post-ACA, poor quality treatment would unlikely effect our results 
negatively. 
 
CONCLUSIONS 
 CRC incidence and mortality in Kentucky is one of the highest in the United States. ACA 
Medicaid expansion has positively affected insurance coverage in this population leading to 
improved CRC screening and improved short-term survival. Future long-term survival studies 
are needed, but the short-term benefits of the ACA expansion have bridged a gap in CRC 
disparities in Kentucky. 
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Table 1. Patient Demographics. 
Patient characteristic n % 
All Kentucky patients, 2011-2016, n = 930,176   
ACA Status    
  Pre-ACA* 408,500 43.9 
  Post-ACA 521,676 56.1 
Year screened    
  2011 124,049 13.3 
  2012 142,166 15.3 
  2013 142,285 15.3 
  2014 151,956 16.3 
  2015 194,406 20.9 
  2016 175,314 18.9 
Age    
  20-40 y 75,923 8.2 
  41-50 y 129,050 13.9 
  51-65 y 422,588 45.4 
  66-70 y 118,714 12.8 
  >71 y  183,901 19.8 
Sex    
  Female 517,830 55.7 
  Male 412,346 44.3 
Race    
  White 862,144 92.7 
  Black 55,742 6.0 
  Other 12,290 1.3 
Insurance    
  Not Insured 14,064 1.5 
  Private 444,794 47.8 
  Medicare 367,974 39.6 
  Medicaid 90,308 9.7 
  Other public† 13,036 1.4 
Stage   
 I 2,444 21.8 
 II 2,600 23.2 
 III 2,789 24.9 
 IV 2,224 19.8 
 Unknown 1,152 10.3 
Appalachian Status   
  Non-Appalachian 682,545  73.4 
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  Appalachian 247,631 26.6 
Medicaid patients only, 2011-2016, n = 90,308   
ACA Status   
  Pre-ACA* 20,980 23.2 
  Post-ACA 69,328 76.8 
Year screened    
  2011 6,606 733 
  2012 7,282 8.1 
  2013 7,092 7.8 
  2014 20,394 22.6 
  2015 27,772 (30.8%) 30.8 
  2016 21,162 (23.4%) 23.4 
Age   
  20-40 y 19,762 21.9 
  41-50 y 21,052 23.3 
  51-65 y 48,151 53.3 
  66-70 y 664 0.7 
  >71 y 679 0.8 
Sex   
  Female 56,510 62.6 
  Male 33,798 37.4 
Race   
  White 79,798 88.4 
  Black 8,661 9.6 
  Other 1,849 2.0 
Appalachian Status   
  Non-Appalachian 52,112 57.7 
  Appalachian 38,196 42.3 
Stage   
 I 195 19.7 
 II 207 20.9 
 III 237 24.0 
 IV 255 25.8 
 Unknown 95 9.6 
*Pre-Affordable Care Act (ACA) from 2011 to 2013, post-ACA from 2014-2016. 
†Includes TRICARE, Veterans Affairs, and Military insurances. 
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Table 2. Bivariate Analysis of Pre-Affordable Care Act and Post-Affordable Care Act of 
Colorectal Cancer Screening 
Patient 
characteristic 
Colorectal cancer screening, n (%) 
p Value 
Pre-ACA*, n = 408,500 Post-ACA, n = 521,676 
Age   < 0.0001 
  20-40 y 36,002 (8.8) 39,921 (7.7)  
  41-50 y 59,825 (14.7) 69,225 (13.3)  
  51-65 y 182,362 (44.6) 240,226 (46.0)  
  66-70 y 50,355 (12.3) 68,359 (13.1)  
  >71 y 79,956 (19.6) 103,945 (19.9)  
Sex   < 0.0001 
  Female 228,830 (56.0) 289,000 (55.4)  
  Male 179,670 (44.0) 232,676 (44.6)  
Race   < 0.0001 
  White 379,190 (93) 482,954 (93)  
  Black 23,817 (6) 39,125 (6)  
  Other 5,493 (1) 6,797 (1)  
Insurance     < 0.0001 
  Uninsured 10,617 (2.6) 3,447 (0.7)  
  Private 211,618 (51.8) 233,176 (44.7)  
  Medicare 160,027 (39.2) 207,947 (39.8)  
  Medicaid 20,980 (5.1) 69,328 (13.3)  
  Other public† 5,258 (1.3) 7,778 (1.5)  
Appalachian status   < 0.0001 
  No 306,880 (75.1)  375,665 (72.0)  
  Yes 101,620 (24.9) 146,011 (28.0)  
*Pre-Affordable Care Act (ACA) from 2011 to 2013, post-ACA from 2014-2016. 
†Includes TRICARE, Veterans Affairs, and Military insurances. 
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Table 3. Bivariate Analysis of Pre-Affordable Care Act and Post-Affordable Care Act of 
Colorectal Cancer Incidence Separated by All Insurance Types and Medicaid Only. 
Patient 
characteristic Pre-ACA* (n = 5,665), n (%) Post-ACA (n = 5,776), n (%) p Value 
All insurance types    
Age     < 0.001 
  20-49 y 648 (11.4) 796 (13.8)   
  50-64 y 2,005 (35.4) 2,072 (35.9)   
  65-74 y 1,456 (25.7) 1,468 (25.4)   
  ≥75 y 1,556 (27.5) 1,440 (24.9)   
Sex     0.915 
  Female 2,641 (46.6) 2,687 (46.5)   
  Male 3,024 (53.4) 3,089 (53.5)   
Race     0.007 
  White 5,237 (92.4) 5,302 (91.8)   
  Black 365 (6.5) 368 (6.4)   
  Other 63 (1.1) 106 (1.8)   
Insurance     < 0.001 
  Uninsured 310 (5.5) 67 (1.2)   
  Private 1,788 (31.5) 1,810 (31.3)   
  Medicare 3,001 (53.0) 2,964 (51.3)   
  Medicaid 299 (5.3) 695 (12.0)   
  Other Public† 267 (5.7) 240 (4.2)   
Appalachian status   0.131 
  No 3,888 (68.6)  3,888 (67.3)   
  Yes 1,777 (31.4) 1,888 (32.7)   
Tumor grade   < 0.001 
  
Well-
differentiated 265 (4.7) 437 (7.6)   
  
Moderately-
differentiated 3731 (65.9) 3735 (64.6)   
  
Poorly-
differentiated 424 (7.5) 439 (7.6)   
  
Undifferentiate
d 466 (8.2) 425 (7.4)   
  Unknown 779 (13.7) 740 (12.8)   
Medicaid only    
Age     0.003 
  20-49 y 78 (26.1) 220 (31.7)   
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  50-64 y 183 (61.1) 433 (62.3)   
  65-74 y 19 (6.4) 23 (3.3)   
  75-90 y 19 (6.4) 19 (2.7)   
Sex     0.059 
  Female 152 (50.8) 308 (44.3)   
  Male 147 (49.2) 387 (55.7)   
Race     0.633 
  White 268 (89.6) 603 (86.8)   
  Black 28 (9.4) 83 (11.9)   
  Other 3 (1.0) 9 (1.3)   
Appalachian status   0.008 
  No 160 (53.5) 434 (62.5)   
  Yes 139 (46.5) 261 (37.5)   
Poverty level‡   0.072 
  Low 51 (17.1) 148 (21.3)   
  Moderate 62 (20.7) 166 (23.9)   
  High 72 (24.1) 172 (24.7)   
  Very High 114 (38.1) 209 (30.1)   
High school education§   0.084 
  Very Low 121 (40.5) 217 (31.2)   
  Low 69 (23.1) 167 (24.0)   
  Moderate 85 (28.4) 237 (34.1)   
  High 24 (8.0) 74 (10.7)   
  
*Pre-Affordable Care Act (ACA) from 2011 to 2013, post-ACA from 2014-2016. 
†Includes TRICARE, Veterans Affairs, and Military insurances. 
‡Low, % under poverty level ≤ 16.2; Moderate, % under poverty level 16.3-18.1; High, % under poverty level 18.2-
21.7; Very High, % under poverty level ≥ 21.8. 
§Very Low, % completed high school ≤75.8; Low, % completed high school 75.9-84.4; Moderate, % completed high 
school 84.5-88.1; High, % completed high school ≥88.2. 
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FIGURE LEGENDS: 
Figure 1. Colorectal cancer (CRC) screening by insurance and Appalachian (App) status. CRC 
screening data were obtained from Kentucky Cabinet for Health and Family Services from 
January 1, 2011 to December 31, 2016. (A) All screening cases were separated by insurance 
status depending on pre-Affordable Care Act (ACA) (screening obtained in 2011 to 2013) or 
post-ACA status (screening obtained in 2013-2016). (B) Patients with Medicaid coverage who 
received screening were separated by Appalachian and non-Appalachian status and compared 
pre- and post-ACA implementation. 
 
Figure 2. Colorectal cancer (CRC) incidence by insurance and Appalachian (App) status. CRC 
incidence from January 1, 2011 to December 31, 2016 was obtained from the Kentucky Cancer 
Registry. Pre-ACA was defined as the time period from 2011 to 2013 while post-ACA was from 
2014 to 2016. (A) All cases of CRC were separated out by insurance types and compared before 
and after ACA implementation. (B) Incidence rates of CRC were compared in all Medicaid 
patients separated by Appalachian and non-Appalachian status. 
 
Figure 3. Colorectal cancer (CRC) survival after Affordable Care Act (ACA) by insurance type. 
Survival analysis was performed via Kaplan Meier plots. Pre-ACA was defined as the time 
period between 2011 and 2013, and post-ACA was defined as the time period between 2014 and 
2016. All CRC cases were separated by insurance status: (A) private; (B) Medicaid; (C) 
Medicare; and (D) no insurance. 
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Figure 4. Colorectal cancer (CRC) survival for Medicaid patients after Affordable Care Act 
(ACA) by Appalachian status. Medicaid patients who were diagnosed with CRC were identified 
in the Kentucky Cancer Registry from January 1, 2011 to December 31, 2016. Survival analysis 
was performed with Kaplan Meier plots to evaluate survival in the (A) non-Appalachian and (B) 
Appalachian population. 
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Precis 
Kentucky was an early adopter of the Affordable Care Act Medicaid Expansion, providing a 
significant amount of insurance coverage for poor individuals. As a result, Kentucky had 
increased colorectal cancer screening, earlier diagnosis, and improved survival, especially 
evident in Medicaid and Appalachian patients. 
